KI Potassium Iodide Tablet IOSAT 14 Tablets 130mg
|
|
|
|
|
SKU:
ANIOSAT1
Potassium Iodide protects the thyroid gland from absorption of radioactive iodine by saturating the thyroid glands with stable iodine. The thyroid gland cannot absorb radio active iodine if it is saturated with non-radioactive iodine. Adults will need 1 tablet per day. We recommend at least 28 days per adult or 28 tablets. Children will need 1/2 tablet per day for 28 days or 14 tablets. More details... |
|
|
|
KI Potassium Iodide Tablet IOSAT 14 Tablets 130mg
|
|
|
|
| |
|
Product Details
|
- All IOSAT is fully FDA approved for thyroid blocking in a radiation emergency. Please know that IOSAT is the ONLY full-strength potassium iodide tablet approved by the FDA which can be sold in the US, and is the only product approved for purchase by the US or State governments Also, be aware that IOSAT contains potassium iodide, not iodate, which is not FDA approved and is not legal to sell in the US. Statements by other companies that they are "FDA Approved" or that iodide or iodate are equivalent are untrue (see www.fda.gov).
- Each standard package of IOSAT contains a strip of 14 tablets, with each tablet containing 130 mg of potassium iodide. The tablets are double scored to split easily and cleanly into 65 and 32.5 child doses.
- Each tablet is individually wrapped in a foil blister packet. The product is available with or without an outer transparent plastic film enclosure containing the tablet strip and Patient Product Information brochure.
- Tablets currently being shipped carry an expiration date in 2015.
iOSAT™ is the first "Radiation Protective" or Thyroid Blocking" agent to be sold directly to the general public. Its active ingredient, 130 mg. of potassium iodide (KI), gives virtually complete protection from the most feared consequence of a nuclear accident - a meltdown and release of radioactive iodine into the environment.
Radioactive iodine (primarily I-131) is a waste product of nuclear fission produced in reactors and bombs. Its potential impact on human health is staggering, and it could affect more people (perhaps far more people) than all other radioactive sources combined. US Nuclear Regulatory Commission (NRC) reports indicate that a major release could injure hundreds of thousands of people, and many believe that the government is underestimating the danger.
What makes I-131 so dangerous is that the body can not distinguish it from ordinary iodine. As a result, if it is accidentally swallowed (in contaminated food or water), or inhaled (it can remain in the atmosphere for days), it will be absorbed into the thyroid gland and will remain there long enough to slowly poison its victim. It can take 20 to 30 years, but eventually it can lead to cancer, thyroid damage, growth and birth defects, or death. Children, whose thyroids are especially active, are extremely susceptible to it.
But iOSAT™ protects against radioactive iodine by preventing its absorption by the thyroid gland. iOSAT™ saturates (blocks) the thyroid with stable iodine, "filling it to capacity". Once filled, the gland "turns off" its absorption mechanism, and it will remain off long enough for the radioactive iodine to disappear naturally. This method of protection is extremely safe and effective, and up to 99% of all radiation induced thyroid damage can be avoided by the use of iOSAT™.
The value of potassium iodide was demonstrated following the Chernobyl nuclear accident, where authorities began mass distribution (millions of doses) of KI just hours after the explosion. In the years following the accident in areas where people received the drug, the incidence of thyroid cancer has not increased. But where KI was not distributed, previously rare forms of juvenile thyroid cancer have begun appearing at epidemic rates, with over 11,000 cases reported by the year 2000.
But the radiation did not stop at the Soviet border. In Poland, 300 miles away, authorities watched as radioactive iodine levels began climbing. Soon, authorities felt they had no choice, and doctors ordered a protective dose for every child in the country. These efforts proved successful, and there has been no increase in thyroid cancer in Poland due to Chernobyl. Similar preventative measures took place in other areas throughout Europe, with similar success.
These programs succeeded because most European countries had long stockpiled KI for emergency use in the event of a nuclear accident or war. Planners, therefore, had access to the drug (which should be taken prior to exposure for maximum effectiveness) when it was needed. Unfortunately, similar mass stockpiles are not kept in the United States.
|
|
|
|
